Thunen Shelley B 4

What Happened
Shelley B. Thunen, a member of the board of directors (Outside Director) of LENZ Therapeutics, received an award of 22,100 derivative shares on June 15, 2026. The shares were granted at a $0.00 acquisition price (total cost reported $0), indicating a compensated equity award rather than an open-market purchase. This is an acquisition-type transaction (grant/award), not a sale.

Key Details

• Transaction date: 2026-06-15. Transaction code: A (award/grant). Price: $0.00 per share; total reported value $0.
• Number of shares awarded: 22,100 derivative shares.
• Shares owned after the transaction: Not specified in the provided filing details.
• Vesting note (from filing): Award vests 100% on the earlier of June 15, 2027 or the next annual meeting, provided the reporting person continues to be an Outside Director.
• Timeliness: Filing covers the transaction date 2026-06-15 and was reported for that period (no late filing indicated).

Context
This is a director compensation award (likely restricted shares/RSUs or similar derivative award) that vests in the future; the recipient did not pay cash and did not immediately receive unrestricted stock to sell. Such grants are common for non-employee directors and are compensation-related rather than a direct signal of buying or selling intent.